France: Recommended vaccinations
  General recommendation
  Recommendation for specific groups only
  Catch-up (e.g. if previous doses missed)
 
Vaccination not funded by the National Health system
 
Mandatory vaccination
BirthMonthsYears
2456111216-182561112131415171819242535456574≥ 75
Coronavirus disease (COVID-19)1
COVID-194
tuberculosis
BCG5
diphtheria
D
D
D
D
d
d6
d
d7
tetanus
TT
TT
TT
TT
TT
TT6
TT
TT7
pertussis
acP8
acP
acP
acP
acp
acp9
poliomyelitis
IPV
IPV
IPV
IPV
IPV
IPV6
IPV
IPV7
Haemophilus influenzae type b infection
Hib
Hib
Hib
hepatitis B
HepB10
HepB
HepB
HepB
HepB11
pneumococcal disease2
PCV
PCV
PCV
PCV13+PPSV2312
meningococcal disease3
MenC
MenC
MenC13
measles
MEAS14
MEAS
MEAS
MEAS15
MEAS16
mumps
MUMPS
MUMPS
MUMPS15
MUMPS16
rubella
RUBE
RUBE
RUBE15
RUBE17
human papillomavirus infection
HPV (F/M)18
HPV (F)19
influenza
IIV4
herpes zoster
ZOS20

Version:


Footnotes:

  1. https://www.has-sante.fr/jcms/p_3197104/fr/strategie-vaccinale-contre-le-sars-cov-2
  2. Recommendations for specific at-risk groups: - High-risk older children (5 years and older) and adults should receive a mixed schedule comprising one dose of PCV13 followed by one dose of PPSV23 8 weeks later - Those same high risk individuals should receive a single booster dose of PPSV23 at least 5 years after the first dose of PPSV23
  3. MenB/MenC/MenACYW vaccination: Recommendations for specific at-risk groups apply - refer to the national immunisation policy document for further information (link provided below)
  4. https://www.has-sante.fr/jcms/p_3178533/fr/vaccination-dans-le-cadre-de-la-covid-19
  5. Only recommended for children at high-risk of tuberculosis. Please refer to original document for detailled information on risk-groups.
  6. dTacp-IPV or dTT-IPV if last dTacp-IPV received in the previous 5 years
  7. dTT-IPV every 10 years from 65 years of age
  8. or 8 weeks of age
  9. For those who did not receive a dose of pertussis containing vaccine during the past 5 years, a booster with a quadrivalent vaccine (dTacp-IPV) is recommended at the time of the Td-IPV booster at 25 years. For those aged 25 years and above that did not receive a booster dose, catch-up with a dTacp-IPV vaccine can be proposed until 39 years of age. Recommendation to have an interval of 10 years in adults between a documented pertussis and pertussis re-vaccination.
  10. Babies born to a mother infected with hepatitis B will be offered a first dose at birth simultaneously with HB immunoglobulin, one month of age and 6 month of age. Four doses scheme (0-1-2-6 months) for premature <32 weeks or less than 2 kg. This intervention shall be evaluated at 9 month of age through HBs Ag and anti-HBs antibodies testing, preferably one to four month after the last vaccine dose.
  11. Three doses in a 0, 1, 6 month schedule. From 11 to 15 years, 2 doses in a 0, 6 schedule
  12. For individuals from 5 years with increased risk of invasive pneumococcal disease. the scheme is based upon history of vaccination with PCV vaccines. if not previously vaccinated: PCV13 then PPSV23 (at least 8 weeks in between). If previous vaccination with PPSV23 >one year: PCV13 then PPSV23 (at least 5 years after initial PPSV23). If previously vaccinated with PCV13+PPSV23: further PPSV23 at least 5 years after the last dose.
  13. 1 dose until 24 years
  14. Update 28 June 2013:For a full description of recommendations, please refer to: http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=362. The vaccination from 9 months of age of children entering day care was suspended. Updated recommendations - Measles vaccination for infants under 12 months of age - travelling to countries of high measles endemicity or countries with no measles elimination programmes or in case of exposure to measles cases - One dose of monovalent measles vaccines for infants aged 6 to 8 months. Thereafter 2 doses of MMR as per national recommendations. - Trivalent vaccine can be used for infants aged 9 to 11 months. Thereafter 1 dose of MMR between 12 and 15 month. of MMR are recommended as per national recommendations. In case of exposure to measles cases, administration should occur within 72 hours after exposure to the index case.
  15. 2 doses of MMR one month appart if no previous vaccination ; 1 dose if only one dose previously
  16. Two MMR doses in total among individuals born from 1980
  17. Two MMR doses in total among individuals born from 1980. For rubella, one dose of MMR among unvaccinated woman.
  18. The extension of HPV vaccination to boys aged 11 to 14 with catch-up vaccination for those aged between 15 and 19. This recommendation is applicable since January 1, 2021.
  19. Girls-only catch-up vaccination recommended. Three-dose schedule at 0, 1-2 and 6 months
  20. for further information, please consult: http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=389


More information available at:
https://solidarites-sante.gouv.fr/prevention-en-sante/preserver-sa-sante/vaccination/calendrier-vaccinal


--------------------------------------------------------------------------------


1 Jan. 2018: Revised policy for mandatory vaccination. Extended to 11 antigens in childhood for children born from 1 Jan. 2018.
more information on implementation available at http://solidarites-sante.gouv.fr/IMG/pdf/dossier_de_presse_11_vaccinations_indispensables_obligatoires_au_1er_janvier_2018.pdf



--------------------------------------------------------------------------------

26 April 2016: 2016 vaccination schedule published

Significant changes include:

MEN C: lowering age of dose 1 to 5 months and a dose 2 at 12 months

HPV: Vaccination offered to MSM until 26 years of age. HPV9 recommended in previously non-vaccinated females teenagers and women

PNEUMO ADULTS:
- in persons in an at-risk group; identical scheme whether immunocompromised or not i.e. PCV13 followed by PPS23
- revaccination possible with a non-conjugated vaccine after 5 years interval minimum

VARICELLA: recommendations for contacts of varicella cases are specified

BCG: except Guyane and Mayotte (neonatal vaccination maintained), BCG vaccination of at risk children is recommended from 1 month of age. An IDR prior to vaccination is only recommended for those from 6 years of age (other other specific situation)

ALTERNATIVE SCHEME - SHORTAGE: discussed for pertussis combos, HepA, HepB and BCG

--------------------------------------------------------------------------------

26 March 2015: 2015 vaccination schedule published

--------------------------------------------------------------------------------

22 April 2014: 2014 vaccination schedule launched by the French Ministry of Health.
Relevant changes are as follows but please consult the original document for a full description of the recommendations

Pertussis:
- Infants: indication that the first dose in infants should be given at 2 months (8 weeks). "8 weeks" was added to esnure that the first dose is given as early as possible.

- Adults:
for those who did not receive a dose of pertussis containing vaccine during the past 5 years, a booster with a quadrivalent vaccine (dTacP-IPV) is recommended at the time of the Td-IPV booster at 25 years.
For those aged 25 years and above that did not receive a booster dose, catch-up with a dTacP-IPV vaccine can be proposed until 39 years of age.
Recommendation to have an interval of 10 years in adults between a documented pertussis and pertussis re-vaccination.

- Cocooning strategy
One dose of dTacP-IPV in adults not previously vaccinated or not vaccinated since childhood
One additional dose of dTacP-IPV if last dose for more than 10 years if new cocconing environment.
Interval of one month between a dTIPV and dTacp-IPV vaccination (previously 2 months) a été

- For those in professional environement requiring to be vaccinated against pertussis, recommendations of pertussis vaccination includes those caring for children at parents home and those with regular baby sitting activities.
Booster doses with dTacP-IPV vaccines are recommended at 25, 45 and 65 years of age

HPV:
Both marketed HPV vaccines (Gardasil and Cervarix) can be given in a 2-dose schedule with a 6-month interval between doses at the age of 11-13 years (gardasil) or 11-14 years (Cervarix)

MMR:
Recommendation for the vaccination regimen (2 doses) to be completed by 18 months of age.

--------------------------------------------------------------------------------

19 April 2013:
A simplified vaccination schedule for France issued with the aim to:
- ensure optimal protection at all ages with only the required number of doses
- ensure the schedule is easier to read and remember, and therefore facilitate implementation.

--------------------------------------------------------------------------------


VACCINATIONS RECOMMENDED FOR AT-RISK GROUPS:
Healthcare workers: BCG, diphtheria, tetanus, polio (compulsory); hepatitis B, typhoid (compulsory if exposed - as determined by the occupational doctor); influenza; pertussis (recommended); varicella, measles (recommended if not immune)
Family members living with a new born (mother, father, siblings): pertussis (cocooning strategy - if last dose of pertussis vaccination was given >=10 years before)
People >65: influenza vaccine (people with chronic diseases to prevent from complications)
Pregnant mothers: influenza vaccine
People exposed to sexual or blood transmission: hepatitis B vaccine
High risk group >2 years: pneumococcal vaccine (immunocompromised or with a chronic disease increasing the risk)


For list of detailed recommendations for the individual diseases, please refer to http://www.hcsp.fr/Explore.cgi/pointsur?clef=1 (in French)

2021: The extension of HPV vaccination to boys aged 11 to 14 with catch-up vaccination for those aged between 15 and 19. This recommendation is applicable since January 1, 2021.

--------------------------------------------------------------------------------

Date of last update: 28 Oct 2021

--------------------------------------------------------------------------------